NAD+ Injections: What the Mechanism Actually Tells You (And What It Doesn't)

NAD+ is not a nutrient in the vitamin sense. It's a coenzyme — a molecule that proteins need in order to do their jobs. Think of it as the molecule that shuttles electrons through the mitochondrial machinery that produces ATP. No NAD+, no electron transport chain. No electron transport chain, no ATP. No ATP, no cell. The cascade doesn't get more fundamental than that.

But NAD+ isn't just a passive carrier. It's also the substrate — the raw material — for two enzyme families that have become the center of serious aging research.

Sirtuins are a family of seven proteins (SIRT1 through SIRT7) that regulate everything from inflammatory signaling to mitochondrial biogenesis to DNA repair. They're NAD+-dependent — every deacetylation reaction they run consumes one NAD+ molecule. When NAD+ is abundant, sirtuins are active. When it's depleted — which increasingly describes the aging cell — they aren't. SIRT1 handles stress response and mitochondrial function. SIRT3 localizes to the mitochondria and fine-tunes the enzymes of the electron transport chain itself. SIRT6 works on chromatin and is involved in telomere maintenance and DNA damage signaling.

PARP-1 is the cell's primary DNA-damage sensor. When a strand breaks, PARP-1 tags the site with ADP-ribose polymers — repair-crew markings — and each ADP-ribose unit costs one NAD+ molecule. A cell under high DNA-damage load (which is what "chronic oxidative stress" means in practice) runs a sustained PARP-1 response, drawing down NAD+, which in turn suppresses sirtuin activity, which impairs mitochondrial function, which generates more oxidative stress. It's a loop, and it's not a pleasant one.

Then there's CD38 — arguably the least glamorous actor in this story and possibly the most important one for understanding why NAD+ declines with age. CD38 is an enzyme on immune cells that hydrolyzes NAD+ for its own signaling purposes. Unlike sirtuins and PARP, it doesn't recycle what it uses — it's a consumer in the pure sense. CD38 expression is driven up by chronic low-grade inflammation: IL-6, TNF-alpha, IFN-gamma — the cytokine cocktail that tends to accumulate with age, the one researchers have started calling "inflammaging." Data from mouse models showed that CD38-knockout animals don't experience the NAD+ decline that wild-type animals show with age.* That's not a human trial. But it is a plausible mechanism for why NAD+ falls as reliably as it does — not just because synthesis slows down, but because inflammatory demand goes up.

Camacho-Pereira et al., 2016, Cell Metabolism.

One more piece: NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the salvage pathway — the primary route by which your cells recycle NAD+ precursors back into usable NAD+. NAMPT activity declines with age and is suppressed by some of the same inflammatory signals that upregulate CD38. This matters because it means the aging cell faces a double problem: increased consumption and reduced recycling efficiency. Oral precursors like NMN and NR depend on this salvage machinery to convert to NAD+. If NAMPT is already compromised, that conversion is less efficient than it looks in a healthy young adult.

The honest answer is: meaningfully, and across multiple tissues, over the adult lifespan. The specific percentage varies by tissue, by measurement method, and by individual — so anyone floating a precise universal number is rounding aggressively. What the research describes is a substantial decline between early adulthood and later decades, driven by the compounding pressure of increased consumption (more DNA damage, more inflammatory signaling, upregulated CD38) against a synthesis pathway that becomes less efficient with age.

There's no standard NAD+ blood panel that tells you you're "low" — no equivalent of a ferritin draw or a 25-OH vitamin D. What there is, is a growing body of mechanistic evidence explaining why the decline matters and a pharmacological question about the most efficient way to address it.

Interest in NAD+ therapies has surged by nearly 400% over the past five years as that evidence base has grown.* That's not a clinical outcome. It's a signal that the mechanism is resonating with people who've looked at the biochemistry and decided it's worth their attention.

Google Trends data, 2020–2025.

This is where most guides oversimplify. There are three meaningfully different approaches, and the distinctions matter.

Oral precursors: NMN and NR

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the most heavily studied approaches. The logic is sound: your cells convert these precursors into NAD+ via established enzymatic pathways. A 2018 study in Nature Communications confirmed that oral NR in healthy middle-aged and older adults produced statistically significant increases in blood NAD+ levels.* The effect was real. It was also modest and variable across individuals — which is the part that gets left out of the supplement-industry citation.

Martens et al., 2018, Nature Communications.

The variability is the key word. Conversion efficiency through NAMPT and related enzymes isn't constant — it varies by tissue, by age, and presumably by individual genetics. You're not directly controlling how much NAD+ ends up inside the cells that need it most; you're hoping the conversion machinery runs efficiently enough to get you there.

For younger, metabolically healthy adults with good NAMPT activity, oral precursors may be sufficient. For older adults with compromised salvage pathway function, the efficiency gap is more relevant.

IV infusions

One pilot study found that a continuous infusion of NAD+ produced a 398% increase in plasma NAD+ levels after six hours.* That's the ceiling of what NAD+ delivery can look like, administered in a clinical setting over several hours.

Grant et al., 2019, referenced in PubMed Central.

IV infusions deliver directly to circulation with no absorption variables. The trade-off: clinic visits, infusion time (typically three to four hours for loading doses), and cost per session that runs higher than injections. Rate-dependent sensations — flushing, mild chest tightness, nausea — are common at higher infusion speeds; these are manageable by slowing the rate, but they make rapid high-dose IV administration uncomfortable in a way subcutaneous delivery avoids.

Subcutaneous injections

Subcutaneous administration delivers NAD+ into the tissue just under the skin. You get direct delivery without the conversion dependency of oral precursors and without the clinic time, rate-sensitivity, and per-session cost of IV. Absorption is slower than IV — this is a feature, not a bug, for ongoing maintenance dosing where steady systemic availability matters more than peak plasma concentration.

Whether subcutaneous delivery produces superior intracellular NAD+ enrichment compared to oral precursors, in well-controlled human trials, is a genuine gap in the evidence. The pharmacokinetic argument is compelling. The direct clinical comparison between routes — in humans, at a rigorous level — is still thin. We're accurate about that.

What physician-prescribed subcutaneous dosing offers that the other routes don't: a home-administrable protocol (after appropriate training and physician clearance), meaningful dose precision, and a provider who has reviewed your labs and history before prescribing. That last part is the part the gray market can't replicate.

Mechanistic plausibility: strong. The biochemistry is well-characterized. The role of NAD+ in sirtuin activation, PARP-mediated repair, and mitochondrial function is not disputed. The age-related decline has been reproduced across multiple organisms and tissue types.

Energy metabolism: interesting, early. The most commonly reported early response among patients receiving NAD+ therapy is improved energy and reduced fatigue. One pilot study found fatigue improvement following a single nicotinamide riboside dose in older men.* That's preliminary. It's also consistent with the mechanism — mitochondrial function directly affects cellular energy production. The honest framing is: promising signal, not a proven outcome.

Cognitive function: plausible basis, limited human data. The brain consumes roughly 20% of resting energy expenditure in about 2% of body mass. SIRT1 and SIRT3 are expressed in neurons. Declining NAD+ has been linked in research to conditions involving neurodegeneration.* That's a plausible mechanistic basis for interest in NAD+-related cognitive research. Large, controlled human trials with cognitive endpoints for injectable NAD+ specifically don't yet exist.

cites ScienceDirect research on NAD+ and neurodegeneration.

Longevity endpoints: mechanistic hypothesis, not clinical proof. Sirtuin activation is associated with longevity-related signaling in preclinical models. That is a long distance from "physician-prescribed NAD+ injections extend human healthspan." The former is established. The latter hasn't been tested at scale. Anyone presenting this as settled science is overclaiming, and this audience will notice.

Safety profile: well-characterized. Over 70 published studies suggest NAD+ therapies are generally well-tolerated when appropriately dosed.* The appropriate framing: NAD+ is upstream of several pathways that matter for how well you age. The mechanism justifies serious clinical interest. The human evidence base, particularly for longevity, is still catching up.

Greenwich Medical Spa, citing published safety literature.

This is the gap in most guides. They explain the biochemistry and then skip straight to the protocol order form. Here's the honest version.

NAD+ effects are cumulative, not immediate. Most people don't notice much after a single injection. What tends to emerge over a two-to-six-week loading period is a gradual shift — reported as improved energy, clearer thinking, better sleep quality, and faster recovery from exercise. The variability is real: some people notice changes in the first two weeks; others need a full loading course before anything registers.

A standard loading approach involves more frequent dosing early (two to three times weekly for the first few weeks), followed by a maintenance phase (once weekly, or as determined by your provider based on response). Dosing is individual — common subcutaneous doses range from 100 mg to 200 mg per injection; what's appropriate for you is determined after intake and labs, not from a blog post.

One thing every honest provider will tell you: NAD+ is not a substitute for sleep, training, and nutrition. It is a tool for people who are already doing those things and want to address a specific biochemical gap. Lifestyle optimization has to run parallel, not downstream.

There is a gray market for NAD+ — you can find subcutaneous vials and IV bags from sellers who operate in the same unregulated space as gray-market peptides. The parallel is direct: the molecule might be exactly what the label claims. The sterility, dosing accuracy, and absence of contaminants — those are questions you're answering with trust in a seller who has no accountability structure and no license at stake.

This isn't a morality lecture. It's a quality-of-evidence argument. When you're introducing something directly into subcutaneous tissue or a vein, "probably pharmaceutical-grade" is a strange standard. One analysis found roughly 38% of online-sold peptides met basic purity standards* — which is the same supply chain overlap.

cites analysis of online peptide purity, parallel to ProtocolMD gray-market peptide analysis.

At ProtocolMD, NAD+ injections are compounded at a 503A-licensed pharmacy, prescribed by a US-licensed physician after a proper intake, and dosed based on your specific situation and bloodwork. That structure exists because the injection route requires it. We don't prescribe into the dark.

Profiles that tend to benefit

• Adults 35+ with declining energy, recovery, or cognitive sharpness who've addressed the foundational variables (sleep, training, nutrition) and want a targeted intervention
• People on GLP-1 medications (semaglutide, tirzepatide) — a relevant and under-discussed overlap, since GLP-1 therapy often involves rapid metabolic adaptation and the physiological demand for cellular energy substrate support is elevated during body composition changes
• Athletes or high-output professionals seeking accelerated recovery where the metabolic demand is genuinely elevated
• Individuals with family history or personal concern around neurodegenerative conditions — not a preventive treatment, but a mechanistically relevant area of clinical interest

Contraindications and cautions

Active malignancy warrants careful discussion with an oncologist before starting — sirtuin and PARP pathways are not trivial biochemical considerations in that context. Pregnancy and breastfeeding are contraindications. Patients on anticoagulants, antihypertensives, insulin, or chemotherapy need a full medication review — interactions exist, and they matter. Severe hepatic or renal disease requires specialist input.

Anyone with a history of low blood pressure or arrhythmias should flag this at intake. These aren't disqualifying conditions for every patient, but they change the clinical calculus.

NAD+ injections are well-tolerated in the published literature. The adverse event profile differs meaningfully by route:

Subcutaneous: Local injection-site irritation, mild redness or tenderness. These are manageable with proper technique and site rotation. Systemic side effects are uncommon at standard doses.

IV (for context): Rate-dependent reactions — flushing, mild chest pressure, nausea — are common when infusion speed is too high. Slowing the rate resolves them in virtually every case. These are not NAD+ side effects per se; they're rate-of-delivery effects.

Rare reports include headache and fatigue following high-dose sessions. NAD+ does not accumulate to toxic levels — there is no known toxic dose. That said, "no known toxic dose" is not the same as "dose insensitively." What's prescribed is what's appropriate for your situation, not the maximum that exists.

NAD+ injections are one of three products ProtocolMD launched with — alongside Sermorelin and Glutathione. The decision to start any of them follows the same structure: intake, labs, physician review, individualized protocol. Not because that process is procedurally required (it is), but because it's the only way to know whether the mechanistic rationale applies to your specific situation.

Your sirtuin activity isn't measured on a standard panel. Your CD38 expression or NAMPT efficiency isn't something you can self-assess from symptoms alone. What a physician can assess is your metabolic profile, your history, your goals, and whether the available evidence creates a reasonable case for intervention — at what dose, by what route, and over what timeline.

The mechanism is compelling. The decision of whether it's right for you belongs in a consult, not a blog post. You can't optimize what you refuse to measure. So measure first.

Learn more about NAD+ injections at ProtocolMD →

Book a free consultation →